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While effective polysaccharide vaccines have been developed for meningococ- 
cal groups A and C (15, 25), no such vaccine exists for group B (26). Group B is 
now a  major cause  of meningococcal disease  in  the  United States  (17) and 
abroad.  Group B  meningococci have been subdivided, as have group C,  into 
several distinct serotypes (9,  12) based upon the presence of protein serotype 
antigens located in the outer membrane (11). The majority of both group B and 
group C disease is caused by a  single serotype, type 2  (9,  13, 20). The type 2 
antigens of groups B and C are chemically and serologically identical (11, 20). 
Antibodies against the serotype antigens are bactericidal in the presence of 
complement (7), and the majority of bactericidal antibody in the sera of rabbits 
immunized with group B is directed against the serotype antigen (18). 
Study of meningococcal infection has been hampered by the absence of a 
useful  laboratory  model,  since  most common laboratory  animals,  including 
germ-free animals (19), are resistant to meningococcal challenge. The develop- 
ing chicken embryo is one of the few laboratory animals readily susceptible to 
meningococcal infection. Following challenge, 9-15-day-old chick embryos de- 
velop lesions typical of meningococcal infection in  man such as meningitis, 
sinusitis, and pulmonary infection (3, 4, 23). Ueda et al.  (24) have developed a 
chick embryo model for the study of serum protection against group A meningo- 
cocci.  For intravenous (i.v.) challenge of 12-day-old embryos, they found that 
best protection was obtained when diluted serum was injected simultaneously 
with the bacterial challenge. Based upon the work of Ueda et al.  (24), we have 
used the chick embryo model to investigate the role of type-specific and group- 
specific antibodies in protection against group B meningococcal infection. 
Materials and Methods 
Bacterial  Strains and Growth Conditions.  The group B strains M986,  M981,  and M136  were 
characterized  by  Frasch and  Chapman (7,  8).  The  group B type  2  strain  $946  was  received  from  Dr. 
Harry Feldman, Upstate Medical Center, Syracuse,  N. Y. The group C type 2 strain  138I  was 
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obtained from Dr.  Malcolm Artenstein, Walter Reed Army Medical Center,  Washington, D.  C. 
Strains A-1 and C-11 have been described previously (14). The organisms were grown on Mueller- 
Hinton agar (Difco Laboratories, Detroit, Mich.) and then inoculated into 100 ml trypticase soy 
broth (TSB, ~ Difco Laboratories) and grown overnight on a  gyratory shaker at 37°C.  5 ml of the 
overnight broth culture was inoculated into a  new flask of TSB and grown for 3-4 h  to obtain log 
phase cells for challenge of chick embryos.  Preparation of the challenge dose will be described 
under chick embryo techniques. 
Antigens and Antisera.  Purified group B polysaccharide was prepared as described previously 
(16), as was the type 2 serotype antigen from strains M986 and 138I (11). Preparation of the type- 
specific antisera and hyperimmune rabbit sera used in these studies is described elsewhere (7, 11). 
Hyperimmune goat antisera against group B was prepared as described for hyperimmune rabbit 
sera. Anti-capsular and serotype antibodies were absorbed from sera using aluminum hydroxide 
(alum)-precipitated antigens. The sera could not be absorbed using whole bacterial cell prepara- 
tions since endotoxin, which is highly toxic to the embryos, was released into the sera. Approxi- 
mately 1 mg of antigen was mixed with 1 ml of resuspended 0.05 M  aluminum hydroxide.  The 
alum-precipitated antigen was pelleted and washed once with 0.01 M phosphate-buffered saline, 
pH  7.5.  Undiluted  serum  was  added  to  the  pellet,  resuspended,  and  incubated  at  37°C  with 
occasional mixing for 2 h, then for 1 h at 4°C. The adsorbed serum was separated from the alum by 
centrifugation. 
Group B polysaccharide antibody was purified from goat serum by use of an immunoadsorbent 
column. Sepharose 4B was coupled with 3,3'-diaminedipropylamine as described by Cuatrecasas 
(5). Group B polysaccharide (50 rag) purified as described by Gotschlich et al. (16) was dissolved in 
10 ml of water,  and 20 mg of cyanuric chloride (C3N3C13) was freshly dissolved in N,N-dimethyl- 
formarnide and then added to the polysaccharide. The pH of the reaction mixture was maintained 
at pH  9.0 with NaOH  for a  period of 4  rain.  This reaction mixture was added to 50 ml of the 
derivatized Sepharose suspended in 50 ml of 0.1 M NaHCO,~ pH 7.5. The vessel was closed tightly 
and stirred for 18 h. All reactions were carried out at room temperature. After washing with 0.01 
M phosphate-buffered saline pH 7.5, the immunoadsorbent was poured into a 1.6 × 25-cm column. 
The immunoadsorbent could deplete up to 25 ml of goat serum of its antibody and the latter was 
eluted with 2 M NaC1 at pH 5.5. The column could be used repeatedly. 
Chick Embryo Techniques.  10-day- and 12-day-old chick embryos were used in these studies. 
They were obtained from White Leghorn flocks which had been fed antibiotic-free meal. 10-day-old 
embryos were used for inoculation of the chorioallantoic membrane (CAM). The CAM was exposed 
according to the method of Beveridge and Burnet (1). Graded doses of log phase meningococci in 50 
~l Hanks' balanced salt solution (HBSS, Grand Island Biological Co., Grand Island, N. Y.) were 
dropped onto the intact CAM. The opening in the shell was sealed with a cover slip and Histowax 
(Mathesen, Coleman, and Bell, East Rutherford, N. J.). After 24 h, 100 ~1 of blood was obtained by 
removing the shell at the air sac end and then nicking a blood vessel with a sterile 27-gauge needle 
on a 0.5-ml syringe. The blood was diluted 1:10 in HBSS and plated onto Mueller-Hinton agar. 
12°day-old chick embryos were inoculated i.v. using a  modification of the seroprotection test 
described by Ueda et al.  (24).  The embryos were prepared for inoculation using the method of 
Eichorn (6). Serum dilutions were prepared in HBSS. Log phase organisms were diluted in sterile 
saline to 78% transmission at 540 nm on a  Coleman 44 spectrophotometer (Perkin-Elmer Corp., 
Maywood,  Ill.) in 16  ×  125°mm screw cap tubes. The organisms were then diluted 1,000°fold in 
HBSS to give approximately 4  ×  104 organisms/ml. To reduce the in vitro interaction of antibody 
and  organisms  to  a  minimum,  equal  volumes  of diluted  organisms  and  serum  were  mixed 
immediately before i.v.  inoculation of each set. Each embryo received 100  /~l of the organism- 
serum mixture. The embryos were examined 2-3 h  after inoculation, and any dead embryos were 
eliminated from the experiment as having been killed by the injection procedure. The embryos 
were examined for viability 24 h after challenge. Those embryos that remained alive were bled by 
venipuncture using a  disposable 27°gauge needle on a 0.5-ml syringe. The blood was diluted and 
cultured as for CAM inoculation. 
Direct Bactericidal Assay.  The microbactericidal assay of Frasch and Chapman (7) was used 
as described. 
1  Abbreviations used in this paper:  CAM, chorioallantoic membrane; HBSS, Hanks' balanced 
salt solution; TSB, trypticase soy broth. FRASCH,  PARKE8,  MCNELIS,  AND  GOTSCHLICH 
TABLE  I 
Infection of Chick Embryos Challenged with Different  Group B 
Meningococcal  Strains Inoculated via the Chorioallantoic 
Membrane or Intravenously 
Strain  Serotype  MIDs, CAM*  MLDso i.v.* 
M986  2  1 x  105  <10 
$946  2  1 x  105  <i0 
M981  4  2 x  I0  s  1 x  105 
M136  ii  2 x  i05  <80 
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* MIDs. CAM, minimal dose required to infect  50% of  embryos via the 
chorioallantoic  membrane. 
* MLDs. i.v.,  minimal dose able  to  kill  50% of  embryos when organisms 
given i.v. 
Results 
For  studies  on  protection  of  chick embryos against meningococcal infection  by 
antibody, two routes  were considered:  CAM  and i.v.  challenge.  The minimal 
infective  dose (MIDso)  of  four  group B meningococcal strains  was compared for 
CAM  and i.v.  challenge (Table I).  The chick embryos were examined 24 h after 
challenge for  either  death or  bacteremia. The MID5o for  the 10-day-old  embryos 
challenged by the CAM  route was considerably higher than that seen for i.v. 
challenge. After i.v.  inoculation,  death occurred within 9-12 h, while CAM 
inoculation rarely  caused death by 24 h, even using doses of 107 organisms. 
Ability to cress the CAM  was minimal, as compared to Escherichia  coli K1 
infection  where as few as 10 organisms placed upon the CAM  caused infection 
that was lethal  within 48 h  (unpublished observations).  Attempts were also 
made to use the CAM  inoculation model to study serum protection  whereby 
serum dilutions  and organisms were dropped onto the CAM. Rabbit anti-group 
B meningococcal sera  had little  effect  upon ability  of  the group B organisms to 
invade and cause bacteremia. Furthermore, using CAM  inoculation we were 
unable to  demonstrate any difference  in  virulence  between strain  M981 and the 
other strains (Table I), while i.v. challenge showed M981 to be much less 
virulent. We concluded that CAM  inoculation would not be a useful model 
because large  numbers of organisms were required to cause bacteremia, the 
bacteremia could not  be prevented by antisera,  and CAM  inoculation  could not 
discriminate between strains  of  differing  virulence. 
12-day-old  chick embryos were quite  sensitive  to  i.v.  challenge.  As little  as 10 
organisms of  strains  M986 and $946 caused death of  all  embryos within 24 h. In 
most experiments, between 1,000  and 3,000  organisms were  used,  and  protection 
was measured as  viability  at  24 h. In  control  embryos receiving  organisms only, 
death usually occurred between 9 and 12 h after  challenge. 
Previous studies suggested that the serotype antibody would be protective 
against group B infection,  and that antibodies to the group B polysaccharide 
would be less protective (18).  Sera prepared against the different  group B 
serotypes were bactericidal  only for the homologous serotype (7).  Based upon 
these  earlier  results,  we  wanted to  determine whether antisera  against  different 
immunologically distinct  group B serotypes would also  show primarily type- 
specific  protection.  Antisera against strains  M986, M981, and M136 were tested 322  PROTECTION  AGAINST  GROUP  B  MENINGOCOCCAL  DISEASE 
TABLE  II 
Bactericidal and Protective Effects of Whole Cell Group B Antisera 
Serum  Serotype 
Bactericidal titer  vs. strain 
Protective titer in embryo vs. 
strain 
M986  M981  M136  M986  M951  M136 
Anti-M986  2,7  256  <20  <20  200  40  100 
Anti-M981  4  <20  ->1,280  <20  200  200  ND* 
Anti-M136  11  <20  <20  <20  100  ND  200 
NRS  -  <20  <20  <20  <40  <40  <40 
* ND, not done. 
for bactericidal antibody (Table II).  As expected, M986 and M981 were killed 
only by their homologous antisera. Strain M136 was not killed by its homologous 
antiserum even though anti-M136  serum contains abundant type-specific anti- 
body. This is characteristic for this particular serotype 11 strain (8). Constant 
numbers of three different strains mixed with different serum dilutions were 
injected i.v. into 12-day-old embryos (Table II).  In contrast to the bactericidal 
data,  the protective effects were primarily group specific.  In this and other 
experiments, greater homologous protection occurred which could be the result 
of combined group-specific and  type-specific protection.  However,  the  type- 
specific  protection alone was minimal; absorption of the three antisera with 
alum precipitated group B polysaccharide removed all protective activity. Ab- 
sorption did not alter the type-specific precipitin activity of the sera. Absorption 
with alum precipitated group A polysaccharide  had no effect upon the protective 
effects of the sera, thus ruling out nonspecific effects of the alum. 
Protection against meningococcal infection has been correlated with the pres- 
ence of bactericidal antibodies (14, 22). The group A and group C polysaccharide 
antibodies are strongly bactericidal, whereas the group B polysaccharide anti- 
body is only weakly bactericidal (7, 18). We wanted to know whether quantita- 
tive differences existed between the amount of antibody required to protect 
against the different groups.  We,  therefore, compared human sera obtained 
after vaccination with groups A and C polysaccharide  vaccines (15) with a group 
B  antibody preparation which was  made by  affinity chromatography from 
hyperimmune goat serum, using a purified group B polysaccharide immunoad- 
sorbant (Table III).  Three- to sevenfold less human groups A and C antibody 
(0.03 ~g) was required for protection than goat group B  antibody (0.14 ~g). 
These results were compared with those obtained using rabbit antimeningococ- 
cal sera. The group A serum gave almost identical results to that of the human 
sera, while the group C rabbit antibody showed protection similar to that of 
group B.  We do  not know the exact protective level of rabbit  anti-group B 
antibody, since we were unable to accurately  quantitate the anti-polysaccharide 
antibody in rabbit group B sera, however, the estimated protective level was 
approximately the same as that found using goat antibody. 
The protective effects of group B antisera did appear somewhat unusual, in 
that the group B organisms were not cleared from the blood as efficiently as 
either group A or group C organisms. Table IV shows the different protective FRASCH,  PARKES,  MCNELIS~ AND  GOTSCHLICH 
TABLE III 
Protection of Chick Embryos Against Meningococcal Challenge 
with Antisera Containing Polysaccharide Antibodies and with 
Purified Antibody to Group B Polysaccharide 
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Serum 
MPDs.* against strain 
A-1  C-11  M986(B)  M136(B) 
Pg  ~g 
ECG$ preimmune  NP  NP  -  - 
IG$ preimmune  NP  NP  -  - 
ECG- anti-A  0.05§  -  -  - 
IG- anti-A  0.03  -  -  - 
3170-rabbit anti-A  0.06  -  -  - 
ECG- anti-C  -  0.03  -  - 
IG- anti-C  -  0.03  -  - 
3189- rabbit anti-C  -  0.40  -  - 
B  antibody (goat)  -  NP  0.14  0.23 
NP, no protection; dashes, not tested. 
* MPD~,,  the  minimal  protective  dose  is the  amount of antibody  re- 
quired to prevent death at 24 h  in 50% of embryos against a challenge 
of 1-3  x  10  ~ organisms. 
Laboratory personnel vaccinated with Group A and Group C meningo- 
coccal polysaccharides. 
§ Specific  antibody  concentration  of sera determined  by  quantitative 
precipitation. 
TABLE IV 
Differential Protective Effects of Group A, B, and C Meningococcal 
Polysaccharide Antisera Against Homologous Challenge 
No. of em- 
Serum  Dilution 
bryos 
Dead  Alive 
At 24 h 
Percent 
Alive 
alive 
infected  infected 
Anti-A (ECG) 
Anti-B (Goat) 
1:25  8  3  5  0 
1:100  9  2  7  1 
1:200  5  1  4  1 
1:300  9  4  5  2 
1:50  7  0  7  1 
1:200  7  0  7  4 
1:500  7  3  4  3 
1:1,000  7  5  2  2 
% 
19 
50 
Anti-C (ECG)  1:25  9  2  7  1  16 
1:50  9  0  9  1 
1:100  8  0  8  1 
1:500  4  3  1  1 
Number of organisms in challenge dose: Group A: 5  ×  103; B: 2  ×  10s; C: 2  x  103. 324  PROTECTION  AGAINST  GROUP  B  MENINGOCOCCAL  DISEASE 
effects of human group A, goat group B, and human group C antisera against 
the homologous serogroup. Those embryos that received either group A or C 
antisera and survived 24 h usually had negative blood cultures. In contrast, the 
surviving embryos challenged with group B organisms often remained bacte- 
remic. Rabbit sera against group A gave identical results to that of the human 
group A. Evidence of protection against group B is dependent much more upon 
the challenge dose than either A or C. With group B, protection was seen with a 
challenge of approximately 100 LDI~o, while at slightly higher multiplicity no 
protection could be shown. Although the factors responsible are not clear, group 
B organisms are cleared by the chick embryo with less efficiency than either 
group A or group C meningococci. 
The serotype antigen is the major outer membrane protein and elicits bacteri- 
cidal antibodies (11). However, the serotype antibody appeared to afford rela- 
tively little protection in the chick embryo (Table II). Since these antisera were 
not prepared against purified serotype antigens, the role of serotype antibody 
alone in protection against meningococcal infection of the chick embryo was 
examined. Antiserum 4588, prepared in rabbits against the purified serotype 
antigen  (11), had a  direct bactericidal titer of greater than 1:1,280,  and this 
serum was tested for protection of chick embryos (Table V). There was a much 
lower level of protection than would have been afforded by an antiserum with an 
equal titer raised against whole meningococci. The procedure observed was type 
specific, protecting embryos from infection by both group B and group C type 2 
organisms. 
The relatively poor protective ability of the serotype 2 antiserum may be due 
to the absence of active complement in the 12-day-old chick embryo (2) where 
protection is primarily phagocytic in nature (2). Type-specific antibody is bacte- 
ricidal  only in  the presence of complement. As  seen in  Table V,  the  fresh 
serotype 2 antiserum containing complement showed greater protection than 
heat-inactivated serum. 
The combined effects of antibodies against the serotype antigen and the group 
B pelysaccharide were examined using a  group B type 2 whole cell hyperim- 
mune rabbit serum (no. 881). This serum was examined for its protective effects 
before and after absorption with either alum-precipitated group B polysaccha- 
ride or alum-precipitated group C type 2 serotype antigen (Table V). Serum 881 
had a direct bactericidal titer against strain M986 of 1:1,280 and protected the 
embryos much better than the pure type 2 serum no. 4588, which had a similar 
direct bactericidal titer. As seen previously, the hyperimmune serum provided 
greater protection against the homologous serotype, suggesting the possible 
additive effects of protection by serotype and polysaccharide antibodies. Absorp- 
tion of the  serum with  the  serotype antigen reduced the  MPDs~; however, 
absorption with the group B polysaccharide removed all protective effects of the 
serum, even though we could show that the serotype antibody was undiminished 
after polysaccharide adsorption. Therefore, it was apparent that serotype anti- 
body was maximally effective only in the presence of group-specific antibody, 
that is, the two antibody specificities were synergistic in their effects. 
To study the synergistic effect more directly, purified group B pelysaccharide 
antibody was obtained by affinity chromatography, and this was used together FRASCH,  PARKES,  McNELIS,  AND  GOTSCHLICH 
TABLE  V 
Protection of Chick Embryos with Antisera Against the Type 2 
Serotype Antigen 
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Heat 56°C 
Serum  Adsorb with 
30 rain 
MPDs. vs. strain 
M986  138I  M136 
(B,T2)*  (C,T2)*  (B,Tll)* 
Anti-T2 STA (4,588)  No  -  1:200  -  - 
Yes  -  1:75  1:75  <1:20 
Anti-T2  whole  cell  Yes  -  1:500  -$  1:200 
(881)  Yes  B-CHO  <1:50  -  - 
Yes  A-CHO  1:500  -  - 
Yes  T2 STA  1:100  -  - 
* B,T2, Group B, type 2; C,T2, Group C, type 2; B,Tll,  Group B, type 11. 
* Another Group B anti-T2 whole cell serum had a  MPDso titer of 1:500 against M986 
and 1:350 against 138I. 
with antisera made against the purified type 2 serotype antigen. We chose to 
add a constant amount of one of the antibodies at a concentration below which 
any significant protection occurred and determine whether this low amount of. 
antibody would increase the MPDs,, of the other antibody (Table VI). There was 
a  significant cooperative effect between the two antibodies. Presence of a low 
level of serotype antibody increased the MPDs, of the polysaccharide antibody 
fourfold, while the polysaccharide antibody increased the MPD5. of the type 2 
serum approximately 14-fold. Thus, minute amounts of group B polysaccharide 
antibody have a very significant effect upon the protective ability of the type- 
specific serum. 
Observation of a  strong synergistic effect between group B polysaccharide 
antibody and serotype 2 antibody suggested that a  similar phenomenon may 
also exist with the other meningococcal groups. To test this possibility we chose 
to examine the group C system because both group and type antigens are known 
(12). A group C whole cell serum (anti-C-11)  containing antibody against the 
group C polysaccharide and the homologous serotype antigen was tested for 
protection against  infection by the homologous strain  and  another group  C 
strain of a noncross-reactive serotype (Table VII). The serum gave an approxi- 
mately twofold greater homologous protection which is what we had observed 
for the group B whole cell sera. When we compared ability of the chick embryos 
to clear their infections, those embryos that were challenged with the homolo- 
gous C-11 strain cleared their infection much better than those challenged with 
the other strain. Thus, the effects of group-specific and type-specific antibody 
are probably synergistic for the other meningococcal groups as well. 
Discussion 
We wanted to demonstrate the protective effects of serotype antibody in an in 
vivo model, and we chose the chick embryo because it is susceptible to meningo- 
coccal infection and develops lesions typical of meningococcal infection in man. 
The 12-day-old chick embryo does not possess an active complement system (2), 326  PROTECTION  AGAINST  GROUP  B  MENINGOCOCCAL  DISEASE 
TABLE  VI 
Synergistic Effects  of Antibodies to the Group B Polysaccharide 
and to the Serotype 2 Antigen 
Serum dilution  No. embryos 
At 24 h 
Percent  Dead  Alive  survival 
MPDs.* 
CHO$  1:500  29  5  24  83 
1:1,000  26  8  18  69 
1:2,000  26  5  21  81 
1:6,000  9  9  0  0 
1:2,200 
CHO & STA (1:150)  1:1,000  30  4  26  83 
1:2,000  21  4  17  81 
1:5,000  25  5  20  80 
1:10,000  18  11  7  39 
1:20,000  18  15  3  17 
1:8,900 
STA§  1:50  15  5  10  66 
1:100  15  12  3  20 
1:150  12  10  2  17 
1:200  12  12  0  0 
1:70 
STA & CHO (1:6,000) 1:100  11  3  8  73 
1:200  12  4  8  66 
1:500  12  4  8  66 
1:1,000  10  4  6  60 
>1:1,000 
* MPDs,, minimal serum dilution protecting 50% of the embryos as determined by method 
of Reed-Muench. 
CHO, purified goat Group B polysaccharide antibody containing  2.8 mg specific antibody 
per ml. 
§ STA, serum no. 4588 prepared against purified type 2 serotype antigen. 
TABLE  VII 
Protection  of a Group C Antiserum, Anti-C-11, Against the Homologous 
and a Heterologous Group C Strain 
Strain  Serotype  MPD~,** 
Surviving embryos 
No.  Infected  Uninfected  Percent in- 
fected$ 
C-11  NT§  1/519  51  8  43  16 
138I  2  1/292  44  18  26  41 
* The MPDs, serum dilution was calculated by method of Reed and Muench. 
$ For difference  in survival-P <  0.01 with X  2 of 7.56. 
§ NT, nontypable. 
therefore protective effects observed must be primarily opsonic and phagocytic. 
Specific  antibody was  required  for  uptake  by  the  reticuloendothelial system 
because 10 organisms or less proved lethal in the absence of specific antibody. In 
contrast  to  our  expectations,  we  found  that  the  different  group  B  serotype 
antisera prepared  against whole cells showed primarily group-specific protec- 
tion in the chick embryo. The serotype antisera contained both anti-polysaccha- FRASCH,  PARKES,  MCNELIS,  AND  ~HLICH  327 
ride and anti-serotype antibodies (10). These findings indicate that antibody 
against the serotype antigen, although highly bactericidal in presence of com- 
plement,  is only weakly opsonic in the absence of complement, which is in 
agreement with the observations of Roberts (21). In contrast, while the group B 
polysaccharide antibody is only weakly bactericidal (7, 18), it appears to be an 
effective opsonin. The protective effects of the group B antibody were several 
fold less than those for group A antibody, which may be related to the fact that 
group A antibody is beth strongly bactericidal and an effective opsonin (15, 22). 
It should be noted that there were two differences in the response of chick 
embryos to group B  infection as compared to group A  or group C  infection. 
Firstly, the chick embryos cleared their blood steams of beth group A and group 
C organisms with greater efficiency than they did group B organisms in the 
presence of immune rabbit sera. Secondly, demonstration of protection by anti- 
group B sera was much more dependent upon challenge dose than was the case 
with either group A or C sera. Evidently, the group B antibody was less efficient 
in promoting clearance of the organisms.  A  possible interpretation of these 
differences is that the group B organisms are cleared more slowly, therefore 
there is a lower critical challenge dose for group B above which multiplication of 
the organisms exceeds the ability of the reticuloendothelial system to take up 
and kill the organisms. 
A  deficiency of bactericidal antibody has been related to  susceptibility to 
meningococcal disease (14). Failure to demonstrate significant bactericidal anti- 
bodies against the group B polysaccharide does not rule out the possible protec- 
tive effects of a group B polysaccharide vaccine. Our results indicate that group 
B polysaccharide  antibody is primarily opsonic in nature. Very low levels of this 
antibody are strongly synergistic when combined with the serotype antibody. 
The protective effects of the serotype antibody were increased 14-fold with 0.02 
~g of group B polysaccharide antibody, an antibody concentration below detec- 
tion by indirect hemagglutination and by assay in the chick embryo. In a more 
general sense, these findings indicate that undetectable amounts of one anti- 
body may have very significant effects upon assessment of the effects of another 
antibody. 
In light of the poor immunogenicity  of the group B polysaccharide, the protein 
serotype antigen appears to be the most suitable choice for an effective group B 
vaccine. However, these results indicate that the best vaccine may be one that 
includes both the protein and polysaccharide antigens. 
Summary 
Protection against group B meningococcal infection was examined using the 
chick embryo. 12-day-old embryos were challenged intravenously with various 
meningococcal strains.  The  chick embryo has  an  active  reticuloendothelial 
system but lacks functional complement. In this model we found that protection 
against group B infection was primarily group specific. The group B polysaccha- 
ride antibody is an effective opsonin, but is a very poor bactericidal antibody. In 
contrast, the serotype antibody was bactericidal but only slightly protective in 
the chick embryo where protection is primarily phagocytic  in nature. The group- 
specific and type-specific  antibodies are strongly synergistic. Minute amounts of 328  PROTECTION  AGAINST  GROUP  B  MENINGOCOCCAL  DISEASE 
group  B  polysaccharide  antibody  caused  a  very  significant  increase  in  the 
protective effects of the serotype antibody. 
Received for publication 16 April 19 76. 
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